RMD

Balanced Portfolio

Balanced Portfolio Update: Resmed Rallies on Earnings

ResMed Inc.(RMD) pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. and lower costs for consumers and healthcare systems in more than 140 countries.

Balanced Portfolio

Balanced Portfolio Recommendation: Sell Take Profit – Resmed (RMD)

Sell Take Profit – Resmed (RMD). RMD is a global company digital health and cloud-connected medical devices. The Company design innovative solutions to treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Also, its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases

Balanced Portfolio

Balanced Portfolio Recommendation: Switch 2% ResMed (RMD) to Clinuvel Pharmaceuticals Ltd (CUV)

With the recent run in RMD we are looking to bank some profits here at $29 (+20%) while we see further upside in the stock, the risk that further developments in the GLP-1 space could derail this recent run. Particularly a study due from Eli Lily a maker of Zepbound in the next month.

We still prefer exposure in the healthcare space and are recommending a switch of our RMD allocation to Clinuvel (CUV) a skin disease treatment for sufferers of EPP. They are also in Phase 2 of a stroke treatment drug which is looking promising 

Scroll to Top